688331.SHG RemeGen Co. Ltd. A

Healthcare Biotechnology Shanghai Stock Exchange
151.76 CNY
Close of Nov 4, 2026
75.03 157.80
Market cap
CNY 54.0B
P/E
8.2x
P/B
5.39x
ROE
30.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 688331.SHG undervalued?

Graham number
Price151.76
Graham value108.61
Premium39.7%

688331.SHG trades 39.7% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

RemeGen Co. Ltd. A fundamental analysis

No fundamental analysis for RemeGen Co. Ltd. A yet.

RemeGen Co. Ltd. A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About RemeGen Co. Ltd. A

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, ur…

Full company profile